Sign In
Free Newsletter
CosmosID, Resilient Biotics collaborate to advance respiratory health research
Listen to this article
CosmosID, a microbiome analytics company with a genomic sequencing facility in Germantown, Thursday announced a collaboration with Resilient Biotics to explore the microbiome strains that colonize the respiratory tract tissues, a step toward advancing respiratory health research and therapeutic development.
CosmosID will offer a range of next-generation sequencing services and advanced bioinformatic support. Together, the two companies will work on identifying, analyzing and understanding respiratory tract microbiome systems across multiple animal models and carry out comprehensive genomic sequencing of respiratory colonizers from the Resilient Biotics strain collection. The combined effort will expand the understanding of the function and impact of individual strains on overall respiratory health.
Resilient Biotics is a biotechnology company dedicated to exploring the vast potential of the respiratory tract microbiome. With a team of world-class scientists and cutting-edge discovery platform, Resilient Biotics is at the forefront of microbiome research, aiming to improve human and animal health through a deeper understanding of microbial communities.
